首页> 外文OA文献 >Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial
【2h】

Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial

机译:柠檬酸类抗凝剂与肝素相比在需要连续肾脏替代治疗的急性肾损伤患者中的疗效和安全性:一项随机对照试验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A systemic anticoagulation is often required to prevent circuit and filter clotting in ICU patients undergoing continuous renal replacement therapy (CRRT). A regional citrate-based anticoagulation (RCA) does not induce a systemic anticoagulation and prolongs the filter lifespan, but metabolic side-effects have been associated with this therapy. We conducted a randomized controlled trial with patients requiring CRRT to determine whether RCA using a balanced predilution replacement fluid is more effective than heparin in terms of renal replacement delivered dose and safety profile.
机译:在接受连续性肾脏替代治疗(CRRT)的ICU患者中,通常需要全身性抗凝治疗,以防止回路和滤器凝结。基于柠檬酸的区域性抗凝(RCA)不会引起全身性抗凝作用,并可以延长过滤器的使用寿命,但是这种疗法已经引起了新陈代谢的副作用。我们对需要CRRT的患者进行了一项随机对照试验,以确定就肾脏替代给药剂量和安全性而言,使用平衡的预稀释替代液进行的RCA是否比肝素更有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号